How to Reconstitute Epitalon: Bacteriostatic Water vs Sterile Water

What Is Epitalon and Why Does the Diluent Choice Matter?

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from epithalamin, a polypeptide extract of the bovine pineal gland. Researchers have studied it primarily for its reported ability to stimulate telomerase activity and extend telomere length in cell cultures, though human data are sparse. The diluent you choose changes how long the reconstituted solution remains sterile and stable, and picking the wrong one can lead to bacterial contamination or peptide degradation before you finish the vial.

Why Lyophilized Peptides Need Reconstitution

Epitalon is sold as a research compound in lyophilized (freeze-dried) powder form because the peptide degrades quickly in aqueous solution. Lyophilization removes water to arrest hydrolysis and oxidation, preserving the Ala-Glu-Asp-Gly backbone for months at cold storage temperatures. Once you add liquid, the clock starts. The type of liquid determines how long you have.

Bacteriostatic Water vs Sterile Water: The Core Difference

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol (9 mg/mL) as an antimicrobial preservative, which inhibits bacterial growth and allows multi-dose use over approximately 28 days when the vial is stored at 2-8°C. Sterile water for injection (SWFI) contains no preservative, so once the vial is punctured, any introduced organism can proliferate. The USP Chapter 797 compounding standards classify multi-dose vials reconstituted without a preservative as beyond-use within 1-12 hours at room temperature or 24 hours refrigerated, depending on conditions.

For a 10 mg Epitalon vial that you plan to use over a week or two, bacteriostatic water is the correct choice. For a single injection from a newly opened vial, sterile water works.

Step-by-Step Reconstitution Protocol

Proper technique matters as much as the right diluent. Contamination during reconstitution is the most common source of injection-site infections with compounded peptides.

What You Need Before You Start

Gather everything before you open anything:

• 10 mg lyophilized Epitalon vial (research grade)
• 2 mL bacteriostatic water for injection (or sterile water for single use)
• 1 mL or 3 mL leur-lock syringe with 23-25 gauge drawing needle
• 0.3 mL insulin syringe (28-31 gauge, 5/16 inch) for injection
• Alcohol swabs (70% isopropyl)
• Clean, well-lit surface; ideally a dedicated tray

Do not use tap water, saline, or bacteriostatic saline. Saline can cause peptide precipitation depending on the pH and the specific amino acid sequence.

Reconstitution in Six Steps

1. Wash your hands for 20 seconds. Allow them to dry completely before touching any sterile packaging.
2. Swab the rubber septum of the Epitalon vial and the bacteriostatic water vial with separate alcohol swabs. Let both air-dry for 30 seconds. A wet septum can carry alcohol into the solution and denature the peptide.
3. Draw the desired volume of bacteriostatic water (typically 1-2 mL for a 10 mg vial) into the larger syringe.
4. Insert the needle into the Epitalon vial at a 45-degree angle, pressing the needle tip against the glass wall. Inject the water slowly so it runs down the inside of the vial rather than blasting the powder cake directly. Direct high-velocity injection can shear peptide bonds and create aggregates.
5. Do not shake the vial. Swirl gently in a circular motion for 15-20 seconds until the powder dissolves completely. The solution should be clear and colorless. Discard it if you see cloudiness, particulates, or any color.
6. Label the vial with the reconstitution date and concentration, then refrigerate at 2-8°C. Keep it away from the freezer and away from light.

Calculating Your Concentration

The concentration depends on how much diluent you add to the 10 mg vial:

| Bacteriostatic water added | Resulting concentration | Volume per 1 mg dose | |---|---|---| | 1 mL | 10 mg/mL | 0.10 mL (10 units on a U-100 syringe) | | 2 mL | 5 mg/mL | 0.20 mL (20 units on a U-100 syringe) | | 5 mL | 2 mg/mL | 0.50 mL (50 units on a U-100 syringe) |

Most people using Epitalon for research purposes find the 2 mL reconstitution (5 mg/mL) easiest to work with on an insulin syringe because the volumes are readable without magnification.

How to Draw and Inject Using an Insulin Syringe

Insulin syringes are the standard tool for subcutaneous peptide injections because their fine gauge (28-31 G) minimizes tissue trauma and their fixed small volume reduces dosing error.

Reading Insulin Syringe Units

A U-100 insulin syringe holds 100 units per mL. Each unit equals 0.01 mL. If your reconstituted Epitalon is 5 mg/mL and a researcher is using a 1 mg dose, they draw to the 20-unit mark. If the concentration is 10 mg/mL, a 1 mg dose sits at the 10-unit mark. Getting this calculation wrong by a factor of two or ten is the most common dosing error with peptides. Medication calculation errors with insulin syringes used for non-insulin drugs are a documented patient safety concern, which is one reason standardizing your reconstitution volume matters.

Injection Site and Technique

Subcutaneous injection sites for women include the lower abdomen (at least 5 cm from the navel), the outer thigh, and the lateral upper arm. Rotate sites to prevent lipohypertrophy. Pinch a fold of skin, insert the needle at 45-90 degrees depending on body composition (45 degrees for leaner individuals), inject slowly, and withdraw smoothly. Do not recap needles. Dispose in a sharps container.

WomanRx Reconstitution Clarity Framework

Because Epitalon vial sizes and concentrations vary across research suppliers, we developed a three-step clarity check before every injection:

1. Confirm the vial label. Read the mg quantity on the lyophilized vial, not a memory or a photo.
2. Confirm the reconstitution volume. Check your written log for the exact mL you added, not an estimate.
3. Confirm the syringe units. Recalculate mg/mL divided by your intended dose in mg, then convert to syringe units before drawing.

This three-check sequence catches the most common class of error, a mismatch between the labeled concentration and the drawn volume, before the needle enters skin.

Epitalon Dosing: What Research Suggests (and What It Doesn't)

No FDA-approved dosing protocol for Epitalon exists. It is not an approved drug in the United States. The doses discussed below are drawn from published pilot studies and are provided for informational context only, not as a clinical recommendation.

What Human Studies Have Used

The most-cited human pilot work comes from Vladimir Khavinson's group in Russia. A small open-label trial in elderly participants used 10 mg per day administered intravenously or intramuscularly for 10 days, repeated annually. A separate study in the same population assessed pineal and immune function endpoints over multiple years. Telomerase activation data from somatic cell studies show dose-dependent effects in vitro, but these cannot be directly translated into a subcutaneous human dose.

Community-use patterns for subcutaneous self-administration typically range from 5-10 mg per day for 10-20 day courses, but these are not validated by controlled trials.

Life-Stage Considerations for Women

Reproductive years. No data exist on Epitalon use in cycling women. Telomerase activity varies across the menstrual cycle in reproductive tissue, and the implications of exogenous telomerase stimulation at specific cycle phases are entirely unknown.

Perimenopause. Pineal melatonin output declines with age, and some researchers hypothesize that epithalamin-derived peptides may partly restore melatonin regulation. Melatonin secretion decreases significantly after age 40 in women, which provides the biological rationale some clinicians cite. Whether Epitalon produces a meaningful clinical effect on sleep, vasomotor symptoms, or hormonal milieu in perimenopausal women has not been tested in a controlled trial.

Postmenopause. The available human pilot data are in older populations (mean age approximately 60-80 years) and include women. This is the only life stage where any human observational evidence, however limited, exists.

Trying to conceive and pregnancy. See the dedicated section below. Epitalon should not be used.

Stability, Storage, and Red Flags

Storage Conditions After Reconstitution

Reconstituted Epitalon with bacteriostatic water should be stored upright in the refrigerator at 2-8°C, protected from light. Do not freeze the reconstituted solution. Freeze-thaw cycles can cause peptide aggregation and reduce potency. Peptide stability in aqueous solution is sensitive to temperature fluctuations, pH shifts, and light exposure, making consistent cold-chain storage non-negotiable for research use.

Lyophilized (unreconstituted) Epitalon vials should be stored at -20°C or colder, per most research suppliers' specifications, and allowed to equilibrate to room temperature before reconstitution to prevent condensation from entering the vial.

When to Discard

Discard the vial immediately if:

• The solution is cloudy, has visible particles, or has changed color
• More than 28 days have passed since reconstitution with bacteriostatic water
• More than 24 hours have passed since reconstitution with sterile water
• The vial was left unrefrigerated for more than 4 hours
• The septum shows signs of coring (visible rubber particles in the solution)

Benzyl Alcohol in Bacteriostatic Water: Who Should Not Use It

Benzyl alcohol, the preservative in bacteriostatic water, carries specific contraindications. Benzyl alcohol toxicity ("gasping syndrome") has been documented in neonates receiving large cumulative doses. For adults using small injection volumes (0.1-0.5 mL), the benzyl alcohol exposure is trivial. For women who are pregnant, breastfeeding, or who have neonates in the household receiving IV therapy, the theoretical exposure must be discussed with a clinician. In practice, the primary concern is the underlying peptide itself, not the preservative, in the context of pregnancy.

Pregnancy, Lactation, and Contraception

Epitalon is not recommended during pregnancy or lactation. This is not a regulatory classification because Epitalon has no FDA approval and therefore no assigned pregnancy category. The absence of a category does not mean safety.

Human Pregnancy Data

There are no published human studies of Epitalon use during pregnancy. Animal reproductive toxicology studies for this tetrapeptide have not been published in the peer-reviewed literature in a form that permits risk estimation. Given that Epitalon's proposed mechanism involves telomerase activation and epigenetic modification of gene expression, the theoretical risk to a developing embryo, whose telomere biology and epigenome are in active programming, is not trivial. Precautionary avoidance is warranted.

Lactation

No pharmacokinetic data on Epitalon transfer into human breast milk exist. The peptide's small molecular weight (390 Da) and hydrophilic character suggest it could cross into milk, but the oral bioavailability of a tetrapeptide in an infant's gastrointestinal tract is likely very low due to proteolytic degradation. This theoretical reassurance does not substitute for actual safety data. Avoid use while breastfeeding.

Contraception Requirements

Epitalon is not a recognized teratogen under any regulatory framework because it has not been evaluated. Still, because its effects on reproductive tissue, the endometrium, and the developing embryo are unstudied, women using Epitalon for any purpose should use reliable contraception if pregnancy is not intended, and should discontinue use immediately if pregnancy is confirmed or planned.

Women with PCOS who are pursuing fertility treatment should specifically discuss any peptide use with their reproductive endocrinologist. Telomerase activity in granulosa cells and oocyte quality are active areas of research, and the effect of exogenous telomerase-modulating agents on folliculogenesis is not known.

Who This May Be Right For and Who Should Avoid It

This section uses life-stage and condition framing to help you identify where you fall, not to prescribe.

Possible Fit (Research Context Only)

• Postmenopausal women over 60 participating in supervised longevity research, where the existing pilot data, however limited, were actually collected
• Women with a clinician supervising the use within a research protocol that includes baseline labs and monitoring

Should Avoid or Exercise Extreme Caution

• Any woman who is pregnant or trying to conceive
• Women who are breastfeeding
• Women with a personal or family history of cancer. Telomerase is expressed at high levels in most cancer cells, and telomerase activation is a step in cellular immortalization. The theoretical concern about stimulating telomerase in a host with occult malignancy is clinically real and unresolved.
• Women with autoimmune conditions. The available data suggest immune-modulating effects that are not well characterized in people with pre-existing immune dysregulation.
• Women taking immunosuppressants, anticoagulants, or hormone therapy, given unknown interaction potential.
• Women in reproductive years without specific research-protocol supervision.

The Evidence Gap: An Honest Assessment

Women have been systematically underrepresented in peptide research. The Khavinson pilot studies included elderly women but were not powered to detect sex-specific effects, did not track menstrual or hormonal endpoints, and were conducted without the blinding or placebo controls required by modern trial standards. Sex-based differences in telomere biology are documented: women generally have longer telomeres than age-matched men, and the rate of telomere attrition differs across the female lifespan, particularly at menopause. Whether Epitalon interacts differently with female telomere biology than male is entirely unstudied.

Bacteriostatic Water: Sourcing and Quality Standards

Not all bacteriostatic water is equivalent. For subcutaneous injection, use only bacteriostatic water for injection that meets USP 1 monograph standards and is packaged in a sealed, multi-dose vial. Do not use:

• Bacteriostatic saline (0.9% NaCl with benzyl alcohol), which adds sodium chloride and may precipitate with some peptides
• Any bacteriostatic water sold in open containers or transferred to unlabeled vials
• Water from "bacteriostatic water" kits of unverified origin sold alongside research peptides online

Pharmacy-sourced bacteriostatic water for injection (available at most retail and compounding pharmacies without a prescription in the United States) is the safest and most consistent option. It comes in 30 mL multi-dose vials sealed under sterile conditions. The FDA regulates water for injection under 21 CFR Part 210/211 current Good Manufacturing Practice, and USP-compliant products carry that assurance.

Female Conditions This Topic Touches

Epitalon has been loosely discussed in online longevity communities in relation to several conditions common in women:

PCOS. Telomere length has been reported as shorter in women with PCOS compared to age-matched controls in observational data. Whether this creates a rationale for telomerase-stimulating peptides is speculative, and no study has tested Epitalon in PCOS.

Osteoporosis. Epitalamic peptides have been studied in animal models of bone turnover, but no human data in osteoporotic women exist.

Perimenopause and sleep. The pineal-melatonin hypothesis provides a theoretical link to perimenopausal insomnia, but this is mechanistic speculation, not clinical evidence.

Female pattern hair loss. Telomere dysfunction in hair follicle stem cells is an active research topic, but Epitalon has not been studied in alopecia.

None of these theoretical connections constitute a clinical indication. Name them here not to imply efficacy, but because women searching these conditions deserve to know where the evidence ends and speculation begins.